Skip to content

To evaluate the Safety and efficacy of Unani formulations in the treatment of Nephrolithiasis

Clinical Validation of a Unani Pharmocopoeial Formulation SafÅ«f Hajar al-YahÅ«d in HasÄ?h al-Kulya (Nephrolithiasis)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/02/005551
Enrollment
300
Registered
2015-02-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N200- Calculus of kidney Health Condition 2: null- HasÄ?h al-Kulya (Nephrolithiasis)

Interventions

Intervention1: Safūf Hajar-al Yahūd: Safūf Hajar-al Yahūd (Powder), 5g, BD Orally, with water after meals for a period of 8 weeks Control Intervention1: nil: NA

Sponsors

Central Council for Research in Unani Medicine CCRUM New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: •Patients with HasÄ?h al-Kulya (nephrolithiasis) as diagnosed by X-Ray/Ultrasound KUB with calculi measuring between 3 to 6 mm with or without any of the following symptoms: ï?§ Bawl al-Dam (Haematuria) ï?§ Siqlâ?? al-Khasira (Heaviness in the Loin) ï?§ Wajaâ?? al-Khasira (Pain in the Loin) ï?§•History of Recurrent UTI ï?§•History of Recurrence of Renal Stone ï?§•Urine showing Calcium Crystaluria

Exclusion criteria

Exclusion criteria: •Patients having acute condition of nephrolithiasis •Complicated cases of nephrolithiasis requiring surgical intervention •Patients with hydronephrosis, acute symptoms of UTI or any other renal diseases •Patients with serum creatinine > 2mg% •Patients on long-term medications •Patients with cardiac, pulmonary or hepatic diseases •Pregnancy and lactation •Alcohol or drug abuse/ History of alcohol or drug abuse within 6 months prior to baseline

Design outcomes

Primary

MeasureTime frame
Improvement in signs and symptoms of HasÄ?h al-Kulya (Nephrolithiasis)Timepoint: 8 weeks

Secondary

MeasureTime frame
Haematological and biochemical assessment for safety assessmentTimepoint: 8 weeks

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM),

ccrum507@gmail.com9810161758

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026